Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Fitzhugh, Courtney D ^a,b   Hsieh, Matthew M ^a   Allen, Darlene ^a,b   Coles, Wynona A ^a   Seamon, Cassie ^b   Ring, Michael ^b   Zhao, Xiongce ^b   Minniti, Caterina P ^b   Rodgers, Griffin P ^a   Schechter, Alan N ^b   Tisdale, John F ^a   Taylor, James G ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN GLUCURONIDE; CREATININE; HEMOGLOBIN F; HYDROXYUREA; LACTATE DEHYDROGENASE; URIC ACID; ANTISICKLING AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CAUSE OF DEATH; DRUG USE; FEMALE; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; ORGAN INJURY; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SURVIVAL; SURVIVAL TIME; TRICUSPID JET VELOCITY; ADOLESCENT; ANEMIA, SICKLE CELL; BLOOD; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; FEMALE; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957570980     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141706     Document Type: Article

References (32)

1. Bunn HF (1997) Pathogenesis and Treatment of Sickle Cell Disease. N Engl J Med 337: 762-769. PMID: 9287233
2. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death [see comments]. N Engl J Med 330: 1639-1644. PMID: 7993409
3. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C (2005) Outcome of sickle cell anemia: a 4- decade observational study of 1056 patients. Medicine (Baltimore) 84: 363-376.
4. Fitzhugh CD, Lauder N, Jonassaint JC, Telen MJ, Zhao X, Wright EC, et al. (2010) Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol 85: 36-40. doi: 10.1002/ajh.21569 PMID: 20029950
5. Perronne V, Roberts-Harewood M, Bachir D, Roudot-Thoraval F, Delord JM, Thuret I, et al. (2002) Patterns of mortality in sickle cell disease in adults in France and England. The hematology journal: the official journal of the European Haematology Association / EHA 3: 56-60.
6. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O (2006) Circumstances of death in adult sickle cell disease patients. Am J Hematol 81: 858-863. PMID: 16924640
7. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, et al. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. American Journal of Hematology 85: 403-408. doi: 10.1002/ajh.21699 PMID: 20513116
8. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, et al. (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115: 2354-2363. doi: 10.1182/ blood-2009-05-221333 PMID: 19903897
9. Lanzkron S, Carroll CP, Haywood C Jr. (2013) Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Reports 128: 110-116. PMID: 23450875
10. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. (1995) Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia. N Engl J Med 332: 1317-1322. PMID: 7715639
11. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW (1990) Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 322: 1037-1045. PMID: 1690857
12. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. The Journal of clinical investigation 74: 652-656. PMID: 6205021
13. Powars DR, Weiss JN, Chan LS, Schroeder WA (1984) Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 63: 921-926. PMID: 6200161
14. Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS (2013) The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. British Journal of Haematology 161: 852-860. doi: 10.1111/bjh.12323 PMID: 23590693
15. Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, et al. (2005) Mortality in sickle cell patients on hydroxyurea therapy. Blood 105: 545-547. PMID: 15454485
16. Elmariah H, Garrett ME, De Castro LM, Jonassaint JC, Ataga KI, Eckman JR, et al. (2014) Factors associated with survival in a contemporary adult sickle cell disease cohort. American Journal of Hematology 89: 530-535. doi: 10.1002/ajh.23683 PMID: 24478166
17. Steiner CA, Miller JL (2006) Sickle Cell Disease Patients in U.S. Hospitals, 2004. Statistical Brief #21. Healthcare cost and utilization project (HCUP).
18. Gladwin MT, Barst RJ, Gibbs JS, Hildesheim M, Sachdev V, Nouraie M, et al. (2014) Risk factors for death in 632 patients with sickle cell disease in the United States and United kingdom. PloS one 9: e99489. doi: 10.1371/journal.pone.0099489 PMID: 24988120
19. Darbari DS, Wang Z, Kwak M, Hildesheim M, Nichols J, Allen D, et al. (2013) Severe painful vasoocclusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS ONE 8: e79923. doi: 10.1371/journal.pone.0079923 PMID: 24224021
20. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350: 886-895. PMID: 14985486
21. Taylor JG, Ackah D, Cobb C, Orr N, Percy MJ, Sachdev V, et al. (2008) Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol 83: 6-14. PMID: 17724704
22. (2012) Hydroxyurea Drug Label. Bristol-Myers Squibb Company. pp. 1-13.
23. Taylor JGt, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT, Steinberg MH (2008) Chronic hyperhemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 3: e2095. doi: 10.1371/journal.pone.0002095 PMID: 18461136
24. Lanzkron S, Haywood C Jr, Hassell KL, Rand C(2008) Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. Journal of the National Medical Association 100: 968-973. PMID: 18717150
25. Zumberg MS, Reddy S, Boyette RL, Schwartz RJ, Konrad TR, Lottenberg R (2005) Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/ oncologists. American Journal of Hematology 79: 107-113. PMID: 15929107
26. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ (1997) Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 89: 1078-1088. PMID: 9028341
27. Ware RE (2010) How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 115: 5300-5311. doi: 10.1182/blood-2009-04-146852 PMID: 20223921
28. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377: 1663-1672. doi: 10.1016/S0140-6736(11)60355-3 PMID: 21571150
29. Hankins JS, Helton KJ, McCarville MB, Li CS, Wang WC, Ware RE (2008) Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatric blood & cancer 50: 293-297.
30. Nottage K, Ware R, Winter B, Winfred W, Hankins J, Shulkin B, et al. (2013) Hydroxyurea Preserves Splenic Function Among Children with Sickle Cell Anemia. Pediatric Blood and Cancer 60 Supplement 2: S24-S24.
31. Estepp JH, Smeltzer MP, Wang WC, Hoehn ME, Hankins JS, Aygun B (2013) Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. British Journal of Haematology 161: 402-405. doi: 10.1111/bjh.12238 PMID: 23384083
32. Ross JS (2014) Randomized Clinical Trials and Observational Studies Are More Often Alike Than Unlike. JAMA Intern Med.